Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 120 of 120 entries
Sorted by: Best Match Show Resources per page
Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images.

Journal of clinical medicine

Guo P, Xue Z, Jeronimo J, Gage JC, Desai KT, Befano B, García F, Long LR, Schiffman M, Antani S.
PMID: 33804469
J Clin Med. 2021 Mar 01;10(5). doi: 10.3390/jcm10050953.

Uterine cervical cancer is a leading cause of women's mortality worldwide. Cervical tissue ablation is an effective surgical excision of high grade lesions that are determined to be precancerous. Our prior work on the Automated Visual Examination (AVE) method...

Cite
Guo P, Xue Z, Jeronimo J, et al. Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. J Clin Med. 2021;10(5)doi: 10.3390/jcm10050953.
Guo, P., Xue, Z., Jeronimo, J., Gage, J. C., Desai, K. T., Befano, B., García, F., Long, L. R., Schiffman, M., & Antani, S. (2021). Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. Journal of clinical medicine, 10(5), . https://doi.org/10.3390/jcm10050953
Guo, Peng, et al. "Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images." Journal of clinical medicine vol. 10,5 (2021). doi: https://doi.org/10.3390/jcm10050953
Guo P, Xue Z, Jeronimo J, Gage JC, Desai KT, Befano B, García F, Long LR, Schiffman M, Antani S. Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. J Clin Med. 2021 Mar 01;10(5). doi: 10.3390/jcm10050953. PMID: 33804469; PMCID: PMC7957626.
Copy Download .nbib Format: NLM
Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Zhao Y, Zhao F, Hu S, Zhang X, Zhang W, Pan Q, Gage JC, Sankaranarayanan R, Qiao Y.
PMID: 32694902
Chin J Cancer Res. 2020 Jun;32(3):383-394. doi: 10.21147/j.issn.1000-9604.2020.03.09.

OBJECTIVE: The accuracy of colposcopy-guided biopsy is key to the success of colposcopic triage in cervical cancer screening programs. However, there is no widely adopted biopsy guideline up to date. Our study aimed to determine whether multi-quadrants biopsy improves...

Cite
Zhao Y, Zhao F, Hu S, et al. Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chin J Cancer Res. 2020;32(3):383-394doi: 10.21147/j.issn.1000-9604.2020.03.09.
Zhao, Y., Zhao, F., Hu, S., Zhang, X., Zhang, W., Pan, Q., Gage, J. C., Sankaranarayanan, R., & Qiao, Y. (2020). Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 32(3), 383-394. https://doi.org/10.21147/j.issn.1000-9604.2020.03.09
Zhao, Yuqian, et al. "Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies." Chinese journal of cancer research = Chung-kuo yen cheng yen chiu vol. 32,3 (2020): 383-394. doi: https://doi.org/10.21147/j.issn.1000-9604.2020.03.09
Zhao Y, Zhao F, Hu S, Zhang X, Zhang W, Pan Q, Gage JC, Sankaranarayanan R, Qiao Y. Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chin J Cancer Res. 2020 Jun;32(3):383-394. doi: 10.21147/j.issn.1000-9604.2020.03.09. PMID: 32694902; PMCID: PMC7369178.
Copy Download .nbib Format: NLM
Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum).

Journal of biomedical optics

Mundo AI, Greening GJ, Fahr MJ, Hale LN, Bullard EA, Rajaram N, Muldoon TJ.
PMID: 32323510
J Biomed Opt. 2020 Apr;25(4):1. doi: 10.1117/1.JBO.25.4.049803.

The erratum notes a correction to Fig. 5 for the published article.

Cite
Mundo AI, Greening GJ, Fahr MJ, et al. Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum). J Biomed Opt. 2020;25(4):1doi: 10.1117/1.JBO.25.4.049803.
Mundo, A. I., Greening, G. J., Fahr, M. J., Hale, L. N., Bullard, E. A., Rajaram, N., & Muldoon, T. J. (2020). Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum). Journal of biomedical optics, 25(4), 1. https://doi.org/10.1117/1.JBO.25.4.049803
Mundo, Ariel I, et al. "Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum)." Journal of biomedical optics vol. 25,4 (2020): 1. doi: https://doi.org/10.1117/1.JBO.25.4.049803
Mundo AI, Greening GJ, Fahr MJ, Hale LN, Bullard EA, Rajaram N, Muldoon TJ. Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum). J Biomed Opt. 2020 Apr;25(4):1. doi: 10.1117/1.JBO.25.4.049803. PMID: 32323510; PMCID: PMC7174893.
Copy Download .nbib Format: NLM
Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation.

Journal of thrombosis and thrombolysis

Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF.
PMID: 27557560
J Thromb Thrombolysis. 2016 Nov;42(4):534. doi: 10.1007/s11239-016-1412-x.

No abstract available.

Cite
Hyun G, Li J, Bass AR, et al. Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation. J Thromb Thrombolysis. 2016;42(4):534doi: 10.1007/s11239-016-1412-x.
Hyun, G., Li, J., Bass, A. R., Mohapatra, A., Woller, S. C., Lin, H., Eby, C., McMillin, G. A., & Gage, B. F. (2016). Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation. Journal of thrombosis and thrombolysis, 42(4), 534. https://doi.org/10.1007/s11239-016-1412-x
Hyun, G, et al. "Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation." Journal of thrombosis and thrombolysis vol. 42,4 (2016): 534. doi: https://doi.org/10.1007/s11239-016-1412-x
Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF. Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation. J Thromb Thrombolysis. 2016 Nov;42(4):534. doi: 10.1007/s11239-016-1412-x. PMID: 27557560.
Copy Download .nbib Format: NLM
Blood-based biomarkers for Alzheimer's disease.

EMBO molecular medicine

Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O.
PMID: 34859598
EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408. Epub 2021 Dec 03.

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up...

Cite
Leuzy A, Mattsson-Carlgren N, Palmqvist S, et al. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2021;14(1):e14408doi: 10.15252/emmm.202114408.
Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood-based biomarkers for Alzheimer's disease. EMBO molecular medicine, 14(1), e14408. https://doi.org/10.15252/emmm.202114408
Leuzy, Antoine, et al. "Blood-based biomarkers for Alzheimer's disease." EMBO molecular medicine vol. 14,1 (2022): e14408. doi: https://doi.org/10.15252/emmm.202114408
Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408. Epub 2021 Dec 03. PMID: 34859598; PMCID: PMC8749476.
Copy Download .nbib Format: NLM
In vivo parameter identification in arteries considering multiple levels of smooth muscle activity.

Biomechanics and modeling in mechanobiology

Gade JL, Thore CJ, Sonesson B, Stålhand J.
PMID: 33934232
Biomech Model Mechanobiol. 2021 Aug;20(4):1547-1559. doi: 10.1007/s10237-021-01462-4. Epub 2021 May 02.

In this paper an existing in vivo parameter identification method for arteries is extended to account for smooth muscle activity. Within this method a continuum-mechanical model, whose parameters relate to the mechanical properties of the artery, is fit to...

Cite
Gade JL, Thore CJ, Sonesson B, et al. In vivo parameter identification in arteries considering multiple levels of smooth muscle activity. Biomech Model Mechanobiol. 2021;20(4):1547-1559doi: 10.1007/s10237-021-01462-4.
Gade, J. L., Thore, C. J., Sonesson, B., & Stålhand, J. (2021). In vivo parameter identification in arteries considering multiple levels of smooth muscle activity. Biomechanics and modeling in mechanobiology, 20(4), 1547-1559. https://doi.org/10.1007/s10237-021-01462-4
Gade, Jan-Lucas, et al. "In vivo parameter identification in arteries considering multiple levels of smooth muscle activity." Biomechanics and modeling in mechanobiology vol. 20,4 (2021): 1547-1559. doi: https://doi.org/10.1007/s10237-021-01462-4
Gade JL, Thore CJ, Sonesson B, Stålhand J. In vivo parameter identification in arteries considering multiple levels of smooth muscle activity. Biomech Model Mechanobiol. 2021 Aug;20(4):1547-1559. doi: 10.1007/s10237-021-01462-4. Epub 2021 May 02. PMID: 33934232; PMCID: PMC8298368.
Copy Download .nbib Format: NLM
Subtilisin inhibitor like protein '.

3 Biotech

Shaikh FK, Gadge PP, Padul MV, Kachole MS.
PMID: 29276657
3 Biotech. 2018 Jan;8(1):19. doi: 10.1007/s13205-017-1040-y. Epub 2017 Dec 13.

No abstract available.

Cite
Shaikh FK, Gadge PP, Padul MV, et al. Subtilisin inhibitor like protein '. 3 Biotech. 2017;8(1):19doi: 10.1007/s13205-017-1040-y.
Shaikh, F. K., Gadge, P. P., Padul, M. V., & Kachole, M. S. (2018). Subtilisin inhibitor like protein '. 3 Biotech, 8(1), 19. https://doi.org/10.1007/s13205-017-1040-y
Shaikh, Faiyaz K, et al. "Subtilisin inhibitor like protein '." 3 Biotech vol. 8,1 (2018): 19. doi: https://doi.org/10.1007/s13205-017-1040-y
Shaikh FK, Gadge PP, Padul MV, Kachole MS. Subtilisin inhibitor like protein '. 3 Biotech. 2018 Jan;8(1):19. doi: 10.1007/s13205-017-1040-y. Epub 2017 Dec 13. PMID: 29276657; PMCID: PMC5726997.
Copy Download .nbib Format: NLM
Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications.

Perspectives in clinical research

Gadge P, Gadge R, Paralkar N, Jain P, Tanna V.
PMID: 30319944
Perspect Clin Res. 2018 Oct-Dec;9(4):155-160. doi: 10.4103/picr.PICR_93_17.

INTRODUCTION: Telmisartan is one of the preferred choices of antihypertensive in patients of diabetes with hypertension (HTN) and lowers blood pressure (BP) effectively.OBJECTIVE: The objective of the study was to determine BP-lowering efficacy of telmisartan monotherapy in patients of...

Cite
Gadge P, Gadge R, Paralkar N, et al. Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications. Perspect Clin Res. 2018;9(4):155-160doi: 10.4103/picr.PICR_93_17.
Gadge, P., Gadge, R., Paralkar, N., Jain, P., & Tanna, V. (2018). Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications. Perspectives in clinical research, 9(4), 155-160. https://doi.org/10.4103/picr.PICR_93_17
Gadge, Pradeep, et al. "Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications." Perspectives in clinical research vol. 9,4 (2018): 155-160. doi: https://doi.org/10.4103/picr.PICR_93_17
Gadge P, Gadge R, Paralkar N, Jain P, Tanna V. Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications. Perspect Clin Res. 2018 Oct-Dec;9(4):155-160. doi: 10.4103/picr.PICR_93_17. PMID: 30319944; PMCID: PMC6176690.
Copy Download .nbib Format: NLM
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.

JAMA neurology

Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, Knopman DS, Lowe V, Bu G, Vemuri P, Graff-Radford J, Jack CR, Petersen RC.
PMID: 34309632
JAMA Neurol. 2021 Sep 01;78(9):1108-1117. doi: 10.1001/jamaneurol.2021.2293.

IMPORTANCE: Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed.OBJECTIVE: To conduct a head-to-head comparison of plasma p-tau181 and p-tau231 measured on...

Cite
Mielke MM, Frank RD, Dage JL, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021;78(9):1108-1117doi: 10.1001/jamaneurol.2021.2293.
Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., & Petersen, R. C. (2021). Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA neurology, 78(9), 1108-1117. https://doi.org/10.1001/jamaneurol.2021.2293
Mielke, Michelle M, et al. "Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes." JAMA neurology vol. 78,9 (2021): 1108-1117. doi: https://doi.org/10.1001/jamaneurol.2021.2293
Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, Knopman DS, Lowe V, Bu G, Vemuri P, Graff-Radford J, Jack CR, Petersen RC. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021 Sep 01;78(9):1108-1117. doi: 10.1001/jamaneurol.2021.2293. PMID: 34309632; PMCID: PMC8314178.
Copy Download .nbib Format: NLM
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.

Journal of clinical medicine

Hendrix JA, Airey DC, Britton A, Burke AD, Capone GT, Chavez R, Chen J, Chicoine B, Costa ACS, Dage JL, Doran E, Esbensen A, Evans CL, Faber KM, Foroud TM, Hart S, Haugen K, Head E, Hendrix S, Hillerstrom H, Kishnani PS, Krell K, Ledesma DL, Lai F, Lott I, Ochoa-Lubinoff C, Mason J, Nicodemus-Johnson J, Proctor NK, Pulsifer MB, Revta C, Rosas HD, Rosser TC, Santoro S, Schafer K, Scheidemantel T, Schmitt F, Skotko BG, Stasko MR, Talboy A, Torres A, Wilmes K, Woodward J, Zimmer JA, Feldman HH, Mobley W.
PMID: 33924960
J Clin Med. 2021 Apr 28;10(9). doi: 10.3390/jcm10091907.

With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer's disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults...

Cite
Hendrix JA, Airey DC, Britton A, et al. Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. J Clin Med. 2021;10(9)doi: 10.3390/jcm10091907.
Hendrix, J. A., Airey, D. C., Britton, A., Burke, A. D., Capone, G. T., Chavez, R., Chen, J., Chicoine, B., Costa, A. C. S., Dage, J. L., Doran, E., Esbensen, A., Evans, C. L., Faber, K. M., Foroud, T. M., Hart, S., Haugen, K., Head, E., Hendrix, S., Hillerstrom, H., Kishnani, P. S., Krell, K., Ledesma, D. L., Lai, F., Lott, I., Ochoa-Lubinoff, C., Mason, J., Nicodemus-Johnson, J., Proctor, N. K., Pulsifer, M. B., Revta, C., Rosas, H. D., Rosser, T. C., Santoro, S., Schafer, K., Scheidemantel, T., Schmitt, F., Skotko, B. G., Stasko, M. R., Talboy, A., Torres, A., Wilmes, K., Woodward, J., Zimmer, J. A., Feldman, H. H., & Mobley, W. (2021). Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Journal of clinical medicine, 10(9), . https://doi.org/10.3390/jcm10091907
Hendrix, James A, et al. "Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study." Journal of clinical medicine vol. 10,9 (2021). doi: https://doi.org/10.3390/jcm10091907
Hendrix JA, Airey DC, Britton A, Burke AD, Capone GT, Chavez R, Chen J, Chicoine B, Costa ACS, Dage JL, Doran E, Esbensen A, Evans CL, Faber KM, Foroud TM, Hart S, Haugen K, Head E, Hendrix S, Hillerstrom H, Kishnani PS, Krell K, Ledesma DL, Lai F, Lott I, Ochoa-Lubinoff C, Mason J, Nicodemus-Johnson J, Proctor NK, Pulsifer MB, Revta C, Rosas HD, Rosser TC, Santoro S, Schafer K, Scheidemantel T, Schmitt F, Skotko BG, Stasko MR, Talboy A, Torres A, Wilmes K, Woodward J, Zimmer JA, Feldman HH, Mobley W. Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. J Clin Med. 2021 Apr 28;10(9). doi: 10.3390/jcm10091907. PMID: 33924960; PMCID: PMC8124643.
Copy Download .nbib Format: NLM
Hospital delivery and neonatal mortality in 37 countries in sub-Saharan Africa and South Asia: An ecological study.

PLoS medicine

Gage AD, Fink G, Ataguba JE, Kruk ME.
PMID: 34851947
PLoS Med. 2021 Dec 01;18(12):e1003843. doi: 10.1371/journal.pmed.1003843. eCollection 2021 Dec.

BACKGROUND: Widespread increases in facility delivery have not substantially reduced neonatal mortality in sub-Saharan Africa and South Asia over the past 2 decades. This may be due to poor quality care available in widely used primary care clinics. In...

Cite
Gage AD, Fink G, Ataguba JE, et al. Hospital delivery and neonatal mortality in 37 countries in sub-Saharan Africa and South Asia: An ecological study. PLoS Med. 2021;18(12):e1003843doi: 10.1371/journal.pmed.1003843.
Gage, A. D., Fink, G., Ataguba, J. E., & Kruk, M. E. (2021). Hospital delivery and neonatal mortality in 37 countries in sub-Saharan Africa and South Asia: An ecological study. PLoS medicine, 18(12), e1003843. https://doi.org/10.1371/journal.pmed.1003843
Gage, Anna D, et al. "Hospital delivery and neonatal mortality in 37 countries in sub-Saharan Africa and South Asia: An ecological study." PLoS medicine vol. 18,12 (2021): e1003843. doi: https://doi.org/10.1371/journal.pmed.1003843
Gage AD, Fink G, Ataguba JE, Kruk ME. Hospital delivery and neonatal mortality in 37 countries in sub-Saharan Africa and South Asia: An ecological study. PLoS Med. 2021 Dec 01;18(12):e1003843. doi: 10.1371/journal.pmed.1003843. eCollection 2021 Dec. PMID: 34851947; PMCID: PMC8635398.
Copy Download .nbib Format: NLM
Blood-based biomarkers for Alzheimer's disease.

EMBO molecular medicine

Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O.
PMID: 34859598
EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408. Epub 2021 Dec 03.

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up...

Cite
Leuzy A, Mattsson-Carlgren N, Palmqvist S, et al. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2021;14(1):e14408doi: 10.15252/emmm.202114408.
Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood-based biomarkers for Alzheimer's disease. EMBO molecular medicine, 14(1), e14408. https://doi.org/10.15252/emmm.202114408
Leuzy, Antoine, et al. "Blood-based biomarkers for Alzheimer's disease." EMBO molecular medicine vol. 14,1 (2022): e14408. doi: https://doi.org/10.15252/emmm.202114408
Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408. Epub 2021 Dec 03. PMID: 34859598.
Copy Download .nbib Format: NLM
Showing 109 to 120 of 120 entries